HomeCompareZLIOF vs ABBV

ZLIOF vs ABBV: Dividend Comparison 2026

ZLIOF yields 6.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZLIOF wins by $11.28M in total portfolio value
10 years
ZLIOF
ZLIOF
● Live price
6.37%
Share price
$1.10
Annual div
$0.07
5Y div CAGR
61.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.38M
Annual income
$9,098,541.86
Full ZLIOF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZLIOF vs ABBV

📍 ZLIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZLIOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZLIOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZLIOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZLIOF
Annual income on $10K today (after 15% tax)
$541.65/yr
After 10yr DRIP, annual income (after tax)
$7,733,760.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ZLIOF beats the other by $7,712,704.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZLIOF + ABBV for your $10,000?

ZLIOF: 50%ABBV: 50%
100% ABBV50/50100% ZLIOF
Portfolio after 10yr
$5.74M
Annual income
$4,561,656.81/yr
Blended yield
79.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZLIOF
No analyst data
Altman Z
1.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZLIOF buys
0
ABBV buys
0
No recent congressional trades found for ZLIOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZLIOFABBV
Forward yield6.37%3.06%
Annual dividend / share$0.07$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR61.8%40.6%
Portfolio after 10y$11.38M$102.3K
Annual income after 10y$9,098,541.86$24,771.77
Total dividends collected$11.16M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZLIOF vs ABBV ($10,000, DRIP)

YearZLIOF PortfolioZLIOF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,731$1,031.04$11,550$430.00+$181.00ZLIOF
2$14,381$1,828.98$13,472$627.96+$909.00ZLIOF
3$18,778$3,390.48$15,906$926.08+$2.9KZLIOF
4$26,787$6,694.51$19,071$1,382.55+$7.7KZLIOF
5$43,103$14,440.62$23,302$2,095.81+$19.8KZLIOF
6$81,257$35,136.56$29,150$3,237.93+$52.1KZLIOF
7$187,107$100,162.61$37,536$5,121.41+$149.6KZLIOF
8$548,969$348,763.80$50,079$8,338.38+$498.9KZLIOF
9$2,134,726$1,547,328.98$69,753$14,065.80+$2.06MZLIOF
10$11,382,698$9,098,541.86$102,337$24,771.77+$11.28MZLIOF

ZLIOF vs ABBV: Complete Analysis 2026

ZLIOFStock

Zoomlion Heavy Industry Science and Technology Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of construction and agricultural machinery in the People's Republic of China and internationally. The company operates through three segments: Construction Machinery, Agricultural Machinery, and Financial Services. It offers concrete machineries, including truck-mounted concrete pumps, trailer-mounted concrete pumps, dry mortar products, concrete placing booms, concrete mixing plants, truck-mounted concrete mixers, truck-mounted line concrete pumps, and self-propelled boom concrete pumps; and cranes, such as truck cranes, all-terrain truck cranes, crawler cranes, and various types of tower cranes. The company also provides road construction and pile foundation machinery, earth working machinery, material handling machineries and systems, specialized vehicles, and vehicle axles; road building and maintenance machinery; hoisting machinery; and forklift trucks and other products for infrastructure and real estate construction. In addition, it offers various agricultural machineries comprising tractors, grain harvesters, and drying machines. Further, the company provides finance leasing, commercial factoring, and bond issuance services. Additionally, it leases and trades in equipment and machineries; researches and manufactures machine software, motor vehicle components, and hydraulic products; and exploits and manages tourism resources. The company was formerly known as Changsha Zoomlion Heavy Industry Science and Technology Development Co., Ltd. and changed its name to Zoomlion Heavy Industry Science and Technology Co., Ltd. in October 2011. Zoomlion Heavy Industry Science and Technology Co., Ltd. was founded in 1992 and is based in Changsha, the People's Republic of China.

Full ZLIOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZLIOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZLIOF vs SCHDZLIOF vs JEPIZLIOF vs OZLIOF vs KOZLIOF vs MAINZLIOF vs JNJZLIOF vs MRKZLIOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.